| Carol Camales, | |
|
167 Vasser Dr, Piscataway, NJ 08854-6628 | |
| (732) 874-0386 | |
| Not Available |
| Full Name | Carol Camales |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 167 Vasser Dr, Piscataway, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063017275 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 26NJ01085700 (New Jersey) | Primary |
| Entity Name | Robert Wood Johnson Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902848625 PECOS PAC ID: 8628065117 Enrollment ID: O20040427001205 |
News Archive
InSight Health Services Holdings Corp. today announced that it had signed a definitive agreement to acquire eight imaging centers in the Phoenix, Arizona, El Paso, Texas, and Las Cruces, New Mexico areas from subsidiaries of MedQuest, Inc. and Novant Health, Inc., for a total purchase price of approximately $8.5 million.
According to Britain's health ministry an additional 7,000 women were fitted with potentially faulty French-made breast implants, raising the total in the U.K.to about 47,000.
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.
Johns Hopkins researchers have documented huge and somewhat puzzling interstate variations in the percentage of emergency versus elective bowel surgeries. Figuring out precisely why the differences occur is critical, they say, because people forced to undergo emergency procedures are far more likely to die from their operations than those able to plan ahead for them.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol Camales, 167 Vasser Dr, Piscataway, NJ 08854-6628 Ph: (732) 874-0386 | Carol Camales, 167 Vasser Dr, Piscataway, NJ 08854-6628 Ph: (732) 874-0386 |
News Archive
InSight Health Services Holdings Corp. today announced that it had signed a definitive agreement to acquire eight imaging centers in the Phoenix, Arizona, El Paso, Texas, and Las Cruces, New Mexico areas from subsidiaries of MedQuest, Inc. and Novant Health, Inc., for a total purchase price of approximately $8.5 million.
According to Britain's health ministry an additional 7,000 women were fitted with potentially faulty French-made breast implants, raising the total in the U.K.to about 47,000.
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.
Johns Hopkins researchers have documented huge and somewhat puzzling interstate variations in the percentage of emergency versus elective bowel surgeries. Figuring out precisely why the differences occur is critical, they say, because people forced to undergo emergency procedures are far more likely to die from their operations than those able to plan ahead for them.
› Verified 8 days ago
Marissa Rangel, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 514 Lynnwood St, Piscataway, NJ 08854 Phone: 848-219-1449 | |
Dr. Naana Asamoah-duodu, DNP, WHNP-BC,RNC-MNN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 60 Coventry Cir, Piscataway, NJ 08854 Phone: 173-282-4496 | |
Margaret M Fleck, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 110 Hospital Rd, Piscataway, NJ 08854 Phone: 732-932-7402 | |
Cheryl Beth Brown, RNC, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 110 Hospital Rd, Piscataway, NJ 08854 Phone: 732-445-3250 | |
Marie Sherly Victorin, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 65 Royal Dr Apt 224, Piscataway, NJ 08854 Phone: 908-800-3974 | |
Beverley Clarke, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5200 Emerson St, Piscataway, NJ 08854 Phone: 732-463-2047 |